Screening for AL Amyloidosis in Smoldering Multiple Myeloma (NCT06365060)
🩺 Plain-English Summary (8th-Grade Level)
In this multicenter study, we will recruit 400 patients 40 years of age or older at 15 centers with a diagnosis of smoldering multiple myeloma (SMM), a group of patients for whom standard of care is observation not treatment. The main goal of this study is to screen for the diagnosis of light-chain amyloidosis (AL) before the onset of symptomatic disease and to develop a training set for a likelihood algorithm.
Who can join: Review the eligibility criteria below.
Location: University of Alabama Hospital — Birmingham, Alabama
Age range: 40 Years
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (13 Sites)
- University of Alabama Hospital — Birmingham, Alabama
- Cedars-Sinai Medical Center — Los Angeles, California
- University of California, San Francisco — San Francisco, California
- Cleveland Clinic Florida, Weston Hospital — Weston, Florida
- Tufts Medical Center — Boston, Massachusetts
- Columbia University Irving Medical Center — New York, New York
- Memorial Sloan Kettering Cancer Center — New York, New York
- Atrium Health Levine Cancer Institute — Charlotte, North Carolina
- UNC Lineberger Comprehensive Cancer Center — Durham, North Carolina
- The Ohio State University Comprehensive Cancer Center — Columbus, Ohio
- UT Southwestern, Harold C. Simmons Comprehensive Cancer Center — Dallas, Texas
- University of Utah, Huntsman Cancer Hospital — Salt Lake City, Utah
- VCU Medical Center — Richmond, Virginia
📞 Contact the Study Coordinator
Phone: (617) 636-6454
Email: raymond.comenzo@tuftsmedicine.org
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Smoldering Multiple Myeloma
- Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant — Tampa, Florida
- A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM — Boston, Massachusetts
- Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma — Rochester, New York
- Smoldering Myeloma High-Risk Patient Observation and Longitudinal Insight Trial — Salt Lake City, Utah
Explore by condition: All Smoldering Multiple Myeloma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.